PROTHENA CORP PUBLIC LTD CO
PROTHENA CORP PUBLIC LTD CO (PRTA): 68 pipeline candidates · 2 upcoming catalysts · ~48 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
47.5 months
D/E 0.12 · 2% dilution
Lead: Phase 3
68 candidates
2 upcoming, next in ~1170d
3 buys · 0 sells (180d)
A transparent, data-derived signal for PROTHENA CORP PUBLIC LTD COacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$444.5M
Cash
$330.3M
Quarterly Burn
$21.0M
Runway
47.5 mo
Revenue
$51.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (68 candidates)
| Drug | Phase |
|---|---|
| Acetaminophen | Phase 1 |
| Acetaminophen 1000 mg/d | Phase 1 |
| Acetaminophen 325Mg Tab | Phase 4 |
| Acetaminophen 4000 mg/d | Phase 1 |
| Acetaminophen 500Mg Tab | Phase 4 |
| Acetylcysteine | Phase 2 |
| anti-thymocyte globulin | Phase 1 |
| Axicabtagene Ciloleucel | Phase 2 |
| Birtamimab | Phase 3 |
| BMS-986446 | Phase 2 |
Showing 10 of 68 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
184
Total value held
$406.3M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 7,551,218 | $73.4M |
| blackrock, inc. | 4,644,160 | $45.1M |
| state street corp | 1,938,498 | $18.8M |
| d. e. shaw & co., inc. | 1,763,347 | $17.1M |
| adar1 capital management, llc | 1,581,443 | $15.4M |
| vanguard portfolio management llc | 1,445,979 | $14.1M |
| morgan stanley | 1,230,448 | $12.0M |
| palo alto investors lp | 1,208,568 | $11.7M |
| two sigma investments, lp | 1,205,978 | $11.7M |
| geode capital management, llc | 1,098,166 | $10.7M |
Showing top 10 of 184 institutional holders of PROTHENA CORP PUBLIC LTD CO. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PROTHENA CORP PUBLIC LTD CO's pipeline?
PROTHENA CORP PUBLIC LTD CO (PRTA) has 68 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PROTHENA CORP PUBLIC LTD CO's lead drug candidate?
PROTHENA CORP PUBLIC LTD CO's most advanced tracked candidate is Acetaminophen (Phase 1) for Healthy Volunteer.
What is PROTHENA CORP PUBLIC LTD CO's next catalyst?
PROTHENA CORP PUBLIC LTD CO's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Optimizing Pain Treatment in Children On Mechanical Ventilation" — expected August 31, 2029.
What is PROTHENA CORP PUBLIC LTD CO's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PROTHENA CORP PUBLIC LTD CO has approximately 47.5 months of cash runway.
What is PROTHENA CORP PUBLIC LTD CO's market capitalization?
PROTHENA CORP PUBLIC LTD CO's market capitalization is approximately $444.5M.
Get the full picture on PROTHENA CORP PUBLIC LTD CO
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.